DOCSLIB.ORG

Host Immunity Vaccines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Ethical Issues and Regulatory Challenges ABOUT THE LEAD AUTHOR Professor Narinder Kumar Mehra, FNA, FNASc, FTWAS, is the former Dean ABOUT THE BOOK (Res) and National Chair of the prestigious All-India Institute of Medical Sciences HOST IMMUN Professor Narinder Mehra is the Honorary Emeritus scientist (AIIMS) New Delhi and currently holds the Honorary position as Emeritus scientist of the Indian Council of Medical Research. He is an internationally acclaimed expert The COVID-19 pandemic has emerged as a serious of ICMR, and former Dean and National Chair of the All-India in the area of Transplant Immunology and Clinical Immunogenetics and is credited human and health crisis affecting over 115 million lives Institute of Medical Sciences, New Delhi. He is an internationally with establishing the speciality for the first time in India. He is a Fellow of several acclaimed expert in the area of Transplant Immunology science academies including the Indian National Science Academy (FNA), National globally with adverse impact on the world economy, and Clinical Immunogenetics, for which his singular efforts Academy of Sciences India (FNASc), Member Honoris Causa of the Hungarian food security, nutrition and life in general. The culminated in establishing this specialty for the first time in Academy of Sciences and ‘Fellow’ of The World Academy of Sciences (FTWAS). disease caused by the novel human beta coronavirus, A recipient of the S.S. Bhatnagar award (1992000), he has over 100 awards to his India, thus facilitating solid organ and hematopoietic stem cell credit and was also honoured with the ‘French Chevalier National Order of Merit’. SARS-CoV-2 has attracted so much attention of the transplants in the country. He has published over 480 research papers in leading international journals. governments and people globally that no other disease His research focus has been on defining biomarkers of disease Dr. Sanjay Madhav Mehendale, MD, MPH, FAMS, served in National Institute I has done in recent times. It is a stark reminder of susceptibility in infectious and autoimmune diseases, influence of Virology (1986-92), National AIDS Research Institute (1992-2010), National TY AND VACC HOST IMMUNITY the ongoing challenge of emerging and re-emerging of HLA matching and alloantibodies on transplant injury, stem Institute of Epidemiology (2010-2016 as Director), National Institute for Research in infectious pathogens and the need for maintaining cell biology and regenerative medicine among others. He played Tuberculosis (2017-18 as Director-in-Charge) before becoming Additional Director- General of the Indian Council of Medical Research. Currently, he is the Director AND constant surveillance through dedicated research efforts an important role in preparing National guidelines for stem cell (Res) at P.D. Hinduja Hospital and Medical Research Centre in Mumbai. He has to understand the basic biology of new organisms and research in India. more than 200 publications to his credit. His areas of research interest include epidemiology of infectious diseases, public health and health systems research, human susceptibilities to them. The observed novel Professor Mehra has been the President of the Indian Immunology clinical trials and socio-behavioural research. He led the first Phase I trials of HIV mutations in the virus suggests that it is still evolving Society, councilor for the International Union of Immunological vaccines in India. VACCINES and may not yet been fully adapted to the human host. Societies, co-chair of the IUIS Gender equality committee and founder Secretary-General of the Federation of Immunological Nevertheless, the recent turn of events provide a new Societies of Asia-Oceania. He is a Fellow of the Indian National hope of ending the global pandemic by achieving I Science Academy, National Academy of Sciences, National NES FOR community immunity through both natural infection as Academy of Medical Sciences, Member Honoris Causa of the well as vaccines. People must continue to observe virus Hungarian Academy of Sciences and ‘Fellow’ of The World Dr. Gaurav Sharma is Assistant Professor in the Department of Translational appropriate behaviour in their day-to-day lives and help and Regenerative Medicine at the Post-Graduate Institute of Medical Education Academy of Sciences (FTWAS). He served as chief Editor of break the cycles of new infection and disease. ‘Frontiers in Immunology’ special issue on ‘Clinical relevance and Research, Chandigarh. His expertise includes histocompatibility and of antibodies in solid organ transplantation’. immunogenetic analysis in relation to solid organ and hematopoietic stem cell transplantation, investigating biomarkers for infectious and autoimmune diseases, This white paper is a tribute to the unprecedented Professor Mehra has nearly 100 awards and academic honors to and research in regenerative medicine. zeal and enthusiasm of the scientific community and of his credit. Some of the significant ones include S.S. Bhatnagar CO A WHITE PAPER the medical professionals working together with the Award of the Council of Scientific and Industrial Research, single most objective of defeating the deathly pandemic. Ranbaxy Science Foundation Award, O.P. Bhasin Science VI Professor Narendra Kumar Arora, MD is the Executive Director of The INCLEN It is a comprehensive treatise with focus on host Foundation Award, Chief of the Army Staff Award and Dr B.R. D Trust International, a ‘not for profit’ organization fostering research and training immunity, vaccines and ethical aspects of COVID-19. Ambedkar award of ICMR for excellence in Medical Research. -19 – to address global health challenges. He is the former Professor of Pediatrics, All The book has 8 chapters, written in easy-to-understand In 2003, the French President, conferred on him the title of India Institute of Medical Sciences, New Delhi, Chair of the National COVID-19 format. ‘Chevalier of the National Order of Merit’. He also received Working Group (NTAGI), CO-Chair of the Independent Allocation Group of COVID- Prof. Narinder K Mehra, FNA the highest International Award from the Iranian Research 19 Vaccine (WHO). He is extensively involved in policy-making, program planning, implementation and evaluation. He has published extensively in the area of public The year 2021 brings in new challenges for the Organization for Science and Technology. He was a member of A health. health authorities of vaccinating the huge population, the international jury for the Else Kroner Fresenius International W bringing hope and confidence that life will return to Award in Immunology and CIHR-IRF joint research projects. HI normal sooner than later. India becomes the greatest Professor Mehra and his group have published more than 480 TE PA success story in the fight against the pandemic and original research papers in leading international journals. His book ‘The HLA System in Medicine and Biology’ received high emerges as one of the only five nations globally to AL SCIEN ON C TI E P A A produce indigenously manufactured vaccines against international acclaim. He has trained 40 Ph.Ds. and more than N C A N D ER is a researcher based in Bhopal with expertise in global health, A E Dr. Anant Bhan I 50 MD/MS postgraduates in the area of clinical Immunogenetics M INDIAN NATIONAL SCIENCE ACADEMY the coronavirus. D Y Y N N I and Transplant Immunology bioethics and health policy. He is an immediate past president of the international I association of bioethics and is an adjunct faculty with the Kasturba Medical college, Bahadur Shah Zafar Marg Manipal. New Delhi-110002 AL SCIEN ON C TI E A A N C A N D A E I M D Y Y N N I I 137 à ~ ; e kf s.; e qoZj HkxZ% lfor à ~ ; e kf s.; e qoZj HkxZ% lfor HOST IMMUNITY AND VACCINES COVID-19 A WHITE PAPER Narinder K. Mehra Sanjay M. Mehendale Gaurav Sharma Narendra K. Arora Anant Bhan AL SCIEN ON C TI E A A N C A N D A E I M D Y Y N N I I INDIAN NATIONAL SCIENCE ACADEMY Bahadur Shah Zafar Marg, New Delhi-110002 à ~ ; e kf s.; e qoZj HkxZ% lfor Citation: Host Immunity and Vaccines for COVID-19 – A White Paper, Indian National Science Academy, New Delhi. pp i-xx and 1-136 © INDIAN NATIONAL SCIENCE ACADEMY E-mail : [email protected], [email protected] Fax : +91-11-23231095, 23235648 EPABX : +91-11-23221931-23221950 (20 lines) Website : www.insaindia.res.in; www.insa.nic.in (for INSA Journals online) INSA Fellows App: Downloadable from Google Play store AUthORS’ AffiliatiOns: Narinder K. Mehra: Hon. Emeritus Scientist of Indian Council of Medical Research and Former Dean and National Chair, All India Institute of Medical Sciences, New Delhi (narin. [email protected]) Sanjay M. Mehendale: Director-Research, PD Hinduja Hospital and Medical Research Centre, Mumbai ([email protected]) Gaurav Sharma: Assistant Professor, Department of Translational and Regenerative Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh (sharma.gaurav@pgimer. edu.in) Narendra K. Arora: Executive Director, International Clinical Epidemiology Network (INCLEN), New Delhi ([email protected]) Anant Bhan: Researcher, Global Health, Bioethics and Health Policy, Bhopal, Madhya Pradesh ([email protected]) Vice-President (Publications/Informatics) Dr. Amit Ghosh, FNA Production Dr. Sudhanshu Aggarwal Published by Dr. Amit Ghosh, Vice-President (Publications/Informatics) on behalf of Indian National Science Academy, Bahadur Shah Zafar Marg, New Delhi 110002 and printed at Angkor Publishers (P) Ltd., B-66, Sector 6, NOIDA-201301; Tel: 0120-4112238 (O); 9910161199, 9871456571 (M) MkW- fouksn dqekj ikWy Hkkjr ljdkj lnL; uhfr vk;ksx] laln ekxZ Dr. Vinod K. Paul ubZ fnYyh&110 001 Government of India MEMBER lR;eso t;rs NATIONAL INSTITUTION FOR TRANSFORMING INDIA NITI Aayog, Parliament Street New Delhi-110 001 Tele.: 23096809/23096820; Fax: 23096810 E-mail: [email protected] FOREWORD Viruses are older than the mankind and are more numerous than all other forms of life put together.
Recommended publications
  • What Do We Know About India's Covaxin Vaccine?

    What Do We Know About India's Covaxin Vaccine?

    FEATURE Tamil Nadu, India COVID-19 VACCINES [email protected] BMJ: first published as 10.1136/bmj.n997 on 20 April 2021. Downloaded from Cite this as: BMJ 2021;373:n997 http://dx.doi.org/10.1136/bmj.n997 What do we know about India’s Covaxin vaccine? Published: 20 April 2021 India has rapidly approved and rolled out Covaxin, its own covid-19 vaccine. Kamala Thiagarajan examines what we know so far. Kamala Thiagarajan freelance journalist Who developed Covaxin? cheapest purchased by any country in the world at 206 rupees per shot for the 5.5 million doses the Covaxin was developed by Indian pharmaceutical government currently has on order. The government company Bharat Biotech in collaboration with the has capped the price of the vaccine sold in the private Indian Council of Medical Research, a government market, with private hospitals able to charge up to funded biomedical research institute, and its 250 rupees.13 subsidiary the National Institute of Virology. Covaxin does not require storage at sub-zero Bharat Biotech has brought to market 16 original temperatures, which would be hard to maintain in vaccines, including for rotavirus, hepatitis B, Zika India’s climate and with the frequent power cuts in virus, and chikungunya.1 The company reportedly rural areas. Covaxin is available in multi-dose vials spent $60-$70m (£43-£50m; €50-€58m) developing and is stable at the 2-8°C that ordinary refrigeration Covaxin.2 can achieve. How does Covaxin work? Bharat Biotech says it has a stockpile of 20 million The vaccine is similar to CoronaVac (the Chinese doses of Covaxin for India and is in the process of vaccine developed by Sinovac)3 in that it uses a manufacturing 700 million doses at its four facilities complete infective SARS-CoV-2 viral particle in two cities by the end of the year.
  • 0 January to July 2021

    0 January to July 2021

    0 www.journalsofindia.com January to July 2021 SCIENCE & TECH ............................................................................................................................................................... 6 1. REUSABLE LAUNCH VEHICLE TECHNOLOGY DEMONSTRATION PROGRAMME(RLV-TD) ................................................. 6 2. GAGANYAAN MISSION ..................................................................................................................................................... 6 3. MARS ORBITER MISSION (MOM) ..................................................................................................................................... 6 4. CHANDRAYAAN MISSION................................................................................................................................................. 7 5. SOLAR MISSION ............................................................................................................................................................... 8 6. ARTEMIS ACCORD ............................................................................................................................................................ 9 7. NATIONAL MISSION ON INTERDISCIPLINARY CYBER-PHYSICAL SYSTEM (NMICPS) ....................................................... 10 8. SMART ANTI-AIRFIELD WEAPON (SAAW) ...................................................................................................................... 10 9. AQUAPONICS ................................................................................................................................................................
  • Bcpct]Ttsbc^Prc U^A Dq[XRV^^S

    Bcpct]Ttsbc^Prc U^A Dq[XRV^^S

    6 < %()(=#%% 53%7==,>3='$()6(=#%% (#-'>3='$()6(=#%% $'()"*$+&,- %( !"# $$%& 2(*3-% (566)(37)% 3 0 4 $5 3 $1 2 0 .8 9 8 ++0 0 .:; . !" . / 01 $ %'( $) '# *' it for the last eight to nine notable achievements to its months, “where is the UN in name in the 75 years of its aking a strong case for a this joint fight. Where is the experience, including the pre- Msignificant role for India effective response.” vention of a third world war, in the United Nations, Prime Focussing on a more “we can’t deny terrorist attacks 0 Minister Narendra Modi on prominent role for India in the shook the world”. Saturday stressed the need for UN and fight against corona, “We have successfully ne of the oldest partners changes in the international the Prime Minister avoided avoided a third world war but Oof the BJP — the body and questioned its posi- making any reference to ongo- we cannot deny many wars Shiromani Akali Dal — which tion in fighting the coron- ing tension at the Line of happened, many civil wars has been with it through thick avirus pandemic. Actual Control (LAC) and happened. Terrorist attack and thin for decades, finally He also assured the global frosty ties with Pakistan in his shook the world. Blood was quit the National Democratic Q community that India will pro- 20-minute speech. He also did spilled. Those were killed were Alliance (NDA) on Saturday, vide corona vaccine to the not respond to Pakistan Prime like you and me. Children left signaling a complete political world as it is the world’s biggest Minister Imran Khan’s remarks the world prematurely,” he said.
  • COVID-19 Vaccines Update Supplement Week Of: 5Th April, 2021

    COVID-19 Vaccines Update Supplement Week Of: 5Th April, 2021

    CARPHA UPDATE FOR Incident Manager / SITUATION REPORT COVID-19 Vaccines Update Supplement Week of: 5th April, 2021 I. Overview of Development and Regulatory Approvals: • 85 candidate vaccines are in clinical development: 16 in Phase 3 trials, and 4 in Phase 4 trials – see Figure in CARPHA COVID-19 Vaccine Regulatory Tracker (Phases tab). • 13 vaccines have received regulatory approvals in various countries, and 16 vaccines are at various stages of engagement with WHO for emergency use listing (EUL). • 4 vaccines have been approved by WHO for Emergency Use Listing: Pfizer-BioNTech’s vaccine: COMIRNATY®, AstraZeneca-SK Bio, AstraZeneca-SII (Covishield), and Janssen-Cilag. • 4 additional vaccines are expected to be approved by WHO in April – Tables 1 and 3. • There are 3 additional vaccines being considered by WHO but these are at the stage of submitting expressions of interest: Bharat Biotech, Clover Biopharmaceuticals-GSK + Dynavax, and BioCubaFarma (Cuba). • The WHO Strategic Advisory Group of Experts on Immunization (SAGE) interim recommendations and background documents are available for vaccines by: Moderna, Pfizer-BioNTech, AstraZeneca-Oxford and Janssen-Cilag at SAGE Interim Guidance. The recommendations provide guidance on the use the vaccines, including use in various groups. • Reports of rare clotting events among vaccinees continue to be assessed by various regulators. The EU's European Medicines Agency (EMA) has stated that there was no evidence to support decisions by regulators to restrict the use of Oxford-AstraZeneca vaccines in some age groups. The WHO maintains that the benefit-risk balance of the vaccine remains favorable. • CARPHA has shared its COVID-19 vaccine regulatory tracker with Member States for viewing as updates are made.
  • 2016 03 28 B M.Pdf

    2016 03 28 B M.Pdf

    file:///C:/Users/Neeraj/Desktop/html/2016_03_28_b_m.htm N O T E ----------------------- ALL ORDINARY MOTION CASES HAVING ADJOURNMENT DATES FROM 23.03.2016 TO 27.03.2016 HAS BEEN SHIFTED TO 28.03.2016 AND FOR THE SAME KINDLY SEE ORDINARY MOTION LIST OF 28.03.2016. ALL CONCERNED TO PLEASE NOTE. ------------------------------------------------------------------------------------------------------ NOTICE ----------------------- It is for the information of all the Advocates/Litigants that as per the decision of Hon'ble Committee, persons belonging to Schedule Castes, Scheduled Tribes, Backward Class (other than Creamy layer), land less labourer, persons holding yellow card, should file a proof along with the affidavit stating therein that he/she belongs to marginalized section of Society. The cases relating to "Crime Against Children, differently abled persons, senior citizens and marginalized sections of Society" will be given priority. The Members of the Bar are requested to provide the information regarding the cases relating to the aforesaid categories which have already been filed by them so that data in the computer can be updated for monitoring of these cases. Sd/- Joint Registrar (Judicial-II) 21.03.2016 ------------------------------------------------------------------------------------------------------- NOTICE ---------------------- Learned members of the Bar are requested to give the list of cases which have to be transferred to the Educational Tribunal, Punjab, in terms of the Jurisdiction conferred under section 7-a(12) of the Punjab affiliated colleges (security of service of employees) Act, 1974, as amended upto late and the Punjab Privately Managed Recognised Schools Employees (security) Act, 1979, in the Registry so that these cases should be listed for hearing. sd/ Registrar Judicial 1 URGENT D.B.
  • V.3 1/25/2021 COVID-19 Vaccine FAQ Sheet

    V.3 1/25/2021 COVID-19 Vaccine FAQ Sheet

    COVID-19 Vaccine FAQ Sheet (updated 1/25/2021) The AST has received queries from transplant professionals and the community regarding the COVID-19 vaccine. The following FAQ was developed to relay information on the current state of knowledge. This document is subject to change and will be updated frequently as new information or data becomes available. What kinds of vaccines are available or under development to prevent COVID-19? There are currently several vaccine candidates in use or under development. In the United States, the Government is supporting six separate vaccine candidates. Several other vaccines are also undergoing development outside of the United States government sponsorship and further information can be found here: • NYTimes Coronavirus Vaccine Tracker: https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine- tracker.html • Washington Post Vaccine Tracker: https://www.washingtonpost.com/graphics/2020/health/covid-vaccine-update- coronavirus/ The types of vaccines are as follows (January 25, 2021) 1: Table 1: Vaccines Under Development Vaccine Type Compound Name Clinical Trial Notes [Sponsor] Phase mRNA mRNA-1273 Phase 3 Emergency use in [Moderna] U.S., E.U., other countries Approved in Canada BNT162b2 [Pfizer] Phase 2/3 Emergency use in U.S., E.U., other countries Also approved in Canada and other countries Replication- AZD1222 Phase 2/3 Emergency use in defective [AstraZeneca] Britain, India, other adenoviral vector countries (not U.S.) Ad26.COV2.S Phase 3 [Janssen] v.3 1/25/2021 Recombinant- NVX-CoV2373 Phase 3 subunit-adjuvanted [Novavax] protein Recombinant SARS- Phase 1/2 CoV-2 Protein Antigen + AS03 Adjuvant [Sanofi Pasteur/GSK] Inactivated CoVaxin [Bharat Phase 3 Emergency Use in coronavirus Biotech] India BBIBP-CorV Phase 3 Approved China, [Sinopharm] Bahrain, UAE; Emergency use elsewhere (not U.S.) Both of the mRNA SARS-CoV-2 vaccines (Moderna, Pfizer) have been approved by Emergency Use Authorization by the U.S.
  • COVID-19 Vaccination Programme: Information for Healthcare Practitioners

    COVID-19 Vaccination Programme: Information for Healthcare Practitioners

    COVID-19 vaccination programme Information for healthcare practitioners Republished 6 August 2021 Version 3.10 1 COVID-19 vaccination programme: Information for healthcare practitioners Document information This document was originally published provisionally, ahead of authorisation of any COVID-19 vaccine in the UK, to provide information to those involved in the COVID-19 national vaccination programme before it began in December 2020. Following authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency being given to the COVID-19 Vaccine Pfizer BioNTech on 2 December 2020, the COVID-19 Vaccine AstraZeneca on 30 December 2020 and the COVID-19 Vaccine Moderna on 8 January 2021, this document has been updated to provide specific information about the storage and preparation of these vaccines. Information about any other COVID-19 vaccines which are given regulatory approval will be added when this occurs. The information in this document was correct at time of publication. As COVID-19 is an evolving disease, much is still being learned about both the disease and the vaccines which have been developed to prevent it. For this reason, some information may change. Updates will be made to this document as new information becomes available. Please use the online version to ensure you are accessing the latest version. 2 COVID-19 vaccination programme: Information for healthcare practitioners Document revision information Version Details Date number 1.0 Document created 27 November 2020 2.0 Vaccine specific information about the COVID-19 mRNA 4 Vaccine BNT162b2 (Pfizer BioNTech) added December 2020 2.1 1.
  • Bharat Biotech Inks Licensing Deal with Washington University School of Medicine in St

    Bharat Biotech Inks Licensing Deal with Washington University School of Medicine in St

    Bharat Biotech Inks Licensing Deal with Washington University School of Medicine in St. Louis to advance COVID-19 Intranasal Vaccine Technology Hyderabad, India, 23 September 2020: Vaccine Innovator, Bharat Biotech announces today, a licensing agreement with Washington University School of Medicine in St. Louis for a novel chimp- adenovirus, single dose intranasal vaccine for COVID-19. Bharat Biotech owns the rights to distribute the vaccine in all markets except USA, Japan and Europe. While the Phase I trials will take place in Saint Louis University’s Vaccine & Treatment Evaluation Unit, Bharat Biotech, upon obtaining the required regulatory approval, will pursue further stages of clinical trials in India and undertake large scale manufacture of the vaccine at its GMP facility located in Genome Valley, Hyderabad. We are proud to collaborate on this innovative vaccine. We envision that we will scale this vaccine to 1 billion doses, translating to 1 billion individuals vaccinated receiving a single-dose regimen. An intranasal vaccine will not only be simple to administer but reduce the use of medical consumables such as needles, syringes, etc., significantly impacting the overall cost of a vaccination drive. Our experience in viral vaccines, manufacturing capabilities, and distribution continue to be our strong suit in ensuring safe, efficacious, and affordable vaccines. It is prudent for Bharat to be involved in diverse but tenable projects to provide a much-needed vaccine against COVID-19 reaches all citizens of the world.” Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech, stated. This intranasal vaccine candidate has shown unprecedented levels of protection in mice studies; the technology and data having been recently published in the prestigious scientific journal Cell and in an editorial in Nature.
  • Editorial 10.5005/Ijmb-24-3-Iv

    Editorial 10.5005/Ijmb-24-3-Iv

    Editorial 10.5005/ijmb-24-3-iv COVID-19 Vaccines: Lets Go for It SARS CoV-2, also christened as COVID-19 is an acute respiratory illness caused by a novel coronavirus which originated from Wuhan China in 2019 and within a short span affected virtually each and every country around the globe, throwing healthcare preparedness and economy out of gear. The world was faced with a pandemic leading to overcrowded hospitals and overflowing mortuaries. Lockdowns imposed in countries jeopardized routine life never to normalize again. India has been among the top three countries with the maximum number of afflicted people. Thankfully , our statistics with respect to mortality is better as compared to the western world. The last year 2020 was completely COVIDISED if we may say so. The world economy is in doldrums and the health infrastructure is overstretched and fatigued. Everytime we feel that the disease is under control, the virus cleverly mutates to become more infective and develops increased ability to escape the immune surveillance. Efforts to develop a vaccine against this scourge were initiated at a war footing across the globe. A number of vaccines were approved for emergency use since the scientific committee didn’t have the time to wait further. In India, two vaccines- Covaxin and Covishield have been approved by the Government of India for mass vaccination. The mammoth program was initiated with first preference for the healthcare workers and frontline warriors. In the next phases, elderly population followed by the rest of the population in a phased manner was planned. It is really incredible and praiseworthy about the immaculate planning and implementation of the initiative in our country where the diversity is both a boon as well as bane.
  • Romanian Journal of Military Medicine

    Romanian Journal of Military Medicine

    Founded 1897 • New Series Romanian Journal of Vol. CXXII • No. 3/2019 • December Military Medicine REVISTA DE MEDICINĂ MILITARĂ • About malpraxis, with love • Current therapeutic strategies for erectile function recovery after radical prostatectomy – literature review and meta-analysis • Toxoplasma Gondii infection and the signs of fetal affection during pregnancy as seen on ultrasound • High values of procalcitonin in non-septic patients with thermal and airway burns • Management of war-related vascular injuries. A civilian surgeon experience in the treatment of war casualties at a secondary care hospital • 3D echo in everyday life: Could it reset our threshold for interventions? • Aptamer as a proper alternative instead of monoclonal antibody in diagnosis and neutralization of menacing biological agents • Alteration of levels of thyroid hormones in acute ischemic stroke and its correlation with severity and functional outcome • Characteristics and complications of supernumerary permanent teeth in a sample of patients examined in a university pedodontics clinic • Development of quantitative real-time RT-PCR assay for detection and viral load determination of Crimean-Congo Hemorrhagic Fever (CCHF) virus • Prioritisation In delivering health services – a military health system example • Why cancer/terminal ill diagnosis unsuccessful in India: a qualitative analysis • Simulation and dynamic analysis of military marching using lower limbs anthropometric data • Drug allergies interpretation based on patient’s history alone may have therapeutic
  • COVID-19 VACCINE FREQUENTLY ASKED QUESTIONS What You Need to Know

    COVID-19 VACCINE FREQUENTLY ASKED QUESTIONS What You Need to Know

    THE REPUBLIC OF UGANDA MINISTRYMINISTRY OF HEALTH COVID-19 VACCINE FREQUENTLY ASKED QUESTIONS What You Need to Know Introduction This document contains the frequently asked questions and answers to provide you with information on the COVID-19 vaccines and why it is important for you to get vaccinated, or encourage those around you to get vaccinated as long as they are eligible. General information about COVID-19 and COVID-19 Vaccine 1. What is the Coronavirus Disease of 2019 (COVID-19) and how does it spread? COVID-19 is an infectious respiratory disease caused by the coronavirus, SARS-CoV-2. The World Health Organisation (WHO) first learned of this new virus from cases in Wuhan city in China on 31st December 2019. The virus can spread from an infected person’s mouth or nose in small liquid particles (droplets) when they cough, sneeze, talk, sing or breathe heavily. The main way the virus spreads is when people are in direct or close contact (less than 1 meter) with an infected person. 1 2. What are the signs and symptoms of COVID-19 infection? • The most common symptoms of COVID-19 are fever, dry cough, and fatigue. • Other symptoms that are less common include loss of taste or smell, nasal congestion, conjunctivitis (red eyes), sore throat, headache, muscle or joint pain, skin rash, nausea or vomiting, diarrhea, chills or dizziness. Symptoms are usually mild. • Some people may get infected and progress to severe disease. Symptoms of severe COVID-19 disease include shortness of breath, loss of appetite, confusion, persistent pain or pressure in the chest, and high temperature (above 38°C).
  • 2017 05 31 O M.Pdf

    2017 05 31 O M.Pdf

    file:///C:/Users/Niraj/Desktop/html/2017_05_31_o_m.htm N O T I C E ---------------------------- Advocates are requested to supply list of the cases which are covered by judgement of five Judges of this Hon'ble High Court in CWP No. 314 of 2001 titled as Suraj Bhan and others Vs State of Haryana and another decided on 22.07.2016 to the Registrar, (Judicial). ----------------------------------------------------------------------------------------------------------- N O T E ------------------------- It is informed to the Advocates/Parties that 29.05.2017 (Monday) has been declared as holiday in this Hon’ble High Court on account of Martyrdom Day of Sri Guru Arjan Dev Ji instead of 16.06.2017 (Friday) and the Saturday falling on 16.12.2017 will be observed as Court Working day in lieu of holiday declared on 29.05.2017 in this Hon’ble High Court. Cases which are pending for 29.05.2017 will be taken up on 30.05.2017. Similarly, 23.11.2017 (Thursday) has been declared as holiday in this Hon’ble High Court on account of Martyrdom Day of Sri Guru Teg Bahadur Ji instead of 24.11.2017 (Friday) and 24.11.2017 already declared holiday will now be observed as working day in this Hon’ble High Court. Cases which are pending for 23.11.2017 will be taken up on 24.11.2017. B.O. of Hon’ble the Chief Justice sd/- Jt. Registrar (J-II) 18.05.2017 ------------------------------------------------------------------------------------------------------------- N O T I C E -------------------------------- It is for the kind notice of the Advocates/parties that Review Applications should be filed complete in all respects and in case of delay, the same will be listed before the appropriate Hon'ble Benches by recording an office note of such defects.